Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

(2019) Miren Zuazo et al.   EMBO Molecular Medicine

Cancer Neoantigens

(2018) Ton N. Schumacher et al.   Annual Review of Immunology

Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity

(2017) Kenji Chamoto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection

(2016) Ran He et al.   NATURE

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles

(2016) Yew Ann Leong et al.   NATURE IMMUNOLOGY

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

PD-1 Blockade Expands Intratumoral Memory T Cells

(2016) A. Ribas et al.   Cancer Immunology Research

Immunotherapy: The Path to Win the War on Cancer?

(2015)   CELL

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phenotype, Function, and Gene Expression Profiles of Programmed Death-1 hi CD8 T Cells in Healthy Human Adults

(2011) Jaikumar Duraiswamy et al.   JOURNAL OF IMMUNOLOGY

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD